The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective

Kawashima, Hideyuki; Zocca, Paolo; Buiten, Rosaly A.; Smits, Pieter C.; Onuma, Yoshinobu; Wykrzykowska, Joanna J.; Winter, Robbert J. de; Birgelen, Clemens von; Serruys, Patrick W.

doi:10.1007/s12471-020-01442-w

Cited by 6 publications

(4 citation statements)

References 94 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the incorporated drugs, new substances have been proposed in these stents, such as zotarolimus, everolimus, and novolimus [ 6 , 68 , 69 , 70 , 71 , 72 ]. Through their diffusion into the vessel wall, these compounds lead to good endothelial coverage, inhibition of vascular restenosis, and suppression of transplant rejection [ 20 , 22 , 52 , 63 ].…”

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

One of the leading causes of morbidity and mortality worldwide is coronary artery disease, a condition characterized by the narrowing of the artery due to plaque deposits. The standard of care for treating this disease is the introduction of a stent at the lesion site. This life-saving tubular device ensures vessel support, keeping the blood-flow path open so that the cardiac muscle receives its vital nutrients and oxygen supply. Several generations of stents have been iteratively developed towards improving patient outcomes and diminishing adverse side effects following the implanting procedure. Moving from bare-metal stents to drug-eluting stents, and recently reaching bioresorbable stents, this research field is under continuous development. To keep up with how stent technology has advanced in the past few decades, this paper reviews the evolution of these devices, focusing on how they can be further optimized towards creating an ideal vascular scaffold.

show abstract

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In current clinical practice in the Netherlands and Belgium, discriminating stent use is highly unlikely, as DES implantation is the standard of care and new-generation DES are widely available [ 20 , 21 ]. Likewise, in our present study, trial participants of all ethnic backgrounds were treated with randomly allocated new-generation DES, which precludes any stent choice.…”

Section: Discussionmentioning

confidence: 99%

“…These studies suggested an increased adverse event risk in ethnic minority patients as compared to non-immigrants [7,13]. Meanwhile, there has been substantial progress in DES design, PCI techniques, and concomitant medication [20,21].…”

Section: Clinical Outcome Of Ethnic Minority Patients With Different ...mentioning

confidence: 99%

Ethnic minorities treated with new-generation drug-eluting coronary stents in two European randomised clinical trials

Ploumen,

Semedo,

Doggen

et al. 2024

Neth Heart J

View full text Add to dashboard Cite

Background Several ethnic minorities have an increased risk of cardiovascular events, but previous European trials that investigated clinical outcome after coronary stenting did not assess the patients’ ethnic background. Aims To compare ethnic minority and Western European trial participants in terms of both cardiovascular risk profile and 1‑year clinical outcome after percutaneous coronary intervention. Methods In the BIO-RESORT and BIONYX randomised trials, which assessed new-generation drug-eluting stents, information on patients’ self-reported ethnic background was prospectively collected. Pooled patient-level data of 5803 patients, enrolled in the Netherlands and Belgium, were analysed in this prespecified analysis. The main endpoint was target vessel failure after 1 year. Results Patients were classified as belonging to an ethnic minority (n = 293, 5%) or of Western European origin (n = 5510, 95%). Follow-up data were available in 5772 of 5803 (99.5%) patients. Ethnic minority patients were younger, less often female, more often current smokers, more often medically treated for diabetes, and more often had a positive family history of coronary artery disease. The main endpoint target vessel failure did not differ between ethnic minority and Western European patients (3.5% vs 4.9%, hazard ratio 0.71, 95% confidence interval 0.38–1.33; p = 0.28). There was also no difference in mortality, myocardial infarction, and repeat revascularisation rates. Conclusions Despite the unfavourable cardiovascular risk profile of ethnic minority patients, short-term clinical outcome after treatment with contemporary drug-eluting stents was highly similar to that in Western European patients. Further efforts should be made to ensure the enrolment of more ethnic minority patients in future coronary stent trials.

show abstract

“…Although more invasive CABG is superior in some groups of patients, they have become the preferred methods of revascularization (4)(5)(6). On the other hand, reocclusion of the coronary arteries due to thrombotic occlusion in acute stages or neointimal hyperplasia (NIH) in the longer periods following minimally invasive techniques has been a major problem after MIT, particularly after bare metal stents (BMS) (7)(8)(9). In the longer period re-occlusion process, multiple factors such as smooth muscle cell (SMC) migration, activation of some cytokines and growth factors, extracellular matrix formation, neutrophil/macrophage activation are involved.…”

Section: Introductionmentioning

confidence: 99%

Atlas drug-eluting coronary stents inhibits neointimal hyperplasia in sheep modeling

Dinc

Yerebakan

2023

Preprint

View full text Add to dashboard Cite

Background: Coronary artery disease (CAD) is one of the leading causes of mortality and morbidity worldwide. Many patients with CAD require mechanical revascularization. However, restenosis after minimally invasive intervention is a major problem for these patients. Fortunately, due to the controlled drug delivery properties of drug-eluting stents (DES), this problem seems to be significantly overcome. In this study, the pharmacodynamic and pharmacokinetic properties of Atlas Drug-eluting Coronary Stents coated with PLGA were evaluated. Materials and Methods This study was carried out in 20 non-atherosclerotic female sheep, divided into four groups that included 4 study and 1 control randomly assigned to each group. The animals in the study groups were stented with Atlas Drug-eluting Coronary Stents and the pharmacodynamic and pharmacokinetic properties were evaluated. Results: A statistically important effectivity of sirolimus on the vascular endothelium was shown. With time, the decrease in sirolimus in blood samples was statistically significant. In the others, no clinically significant side effects were observed. Conclusions The results in this study showed a significant reduction in neointimal hyperplasia after experimental implantation of Atlas Drug-eluting Coronary Stents coated with PLGA polymer. Pharmacokinetic studies also showed that the stent did not release significant left sirolimus after 28 days.

show abstract

The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective

Cited by 6 publications

References 94 publications

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Ethnic minorities treated with new-generation drug-eluting coronary stents in two European randomised clinical trials

Atlas drug-eluting coronary stents inhibits neointimal hyperplasia in sheep modeling

Contact Info

Product

Resources

About